Substance P_Dosage, benefits & legal status
Also known as SP, Tachykinin, Neurokinin-1 agonist
Approved medicine blocks it. One paper suggests putting it on your face.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Substance P?
Plain language first. The technical label stays, but it never stands alone.Overview
Substance P is a pain and inflammation signal, and the useful way to understand it is to look at what approved medicine does with it. The answer is block it. The anti-nausea drugs given during chemotherapy are NK1 receptor antagonists, meaning they stop substance P from acting. In October 2025 the FDA approved elinzanetant for hot flashes in menopause, and its mechanism is described by its maker as inhibition of substance P and neurokinin B. Meanwhile a research group in Denmark is currently recruiting people with migraine to receive substance P by infusion, for the explicit purpose of triggering migraine attacks. Against all of that sits a single 2019 laboratory paper proposing substance P in a gel as an anti-aging skin ingredient. Its three authors all work for the same company, no human skin was tested, and the paper says so in its own discussion.
Substance P is an 11 amino acid tachykinin, residues 58 to 68 of the 129 amino acid protachykinin-1 precursor, reading RPKPQQFFGLM and amidated on the C-terminal methionine at position 68. The same precursor also yields neurokinin A at residues 98 to 107, neuropeptide K and neuropeptide gamma. Substance P is the principal endogenous agonist at the neurokinin-1 receptor, where it mediates pain transmission, neurogenic inflammation, vasodilation and the vomiting reflex. Its pharmacology in approved medicine runs entirely in the blocking direction: every licensed drug acting on this system is an NK1 receptor antagonist. It has no approval as a therapy in any country.
What it's used for
Nothing. It has no approval anywhere. It is given to humans only in research, and in the current studies the purpose is to provoke headache or migraine in order to study the mechanism.
How does Substance P work?
What it does in the body, and where.This page is built around a contradiction in directions. Approved medicine blocks substance P; one paper proposes applying it. Reading the evidence on each side settles which is which.
- 01One precursor, four peptidesThe protachykinin-1 precursor is 129 amino acids long and is cut into several active peptides. Substance P is residues 58 to 68, an 11 amino acid chain reading RPKPQQFFGLM with its terminal methionine amidated. Neurokinin A comes from residues 98 to 107 of the same precursor. Neuropeptide K and neuropeptide gamma are longer products of the same gene. A source describing effects of tachykinins in general is not necessarily describing substance P.
- 02What it does, and the direction medicine tookSubstance P is the main natural agonist at the neurokinin-1 receptor. Through it, substance P transmits pain, drives neurogenic inflammation, dilates blood vessels and participates in the vomiting reflex. Every drug licensed on this system blocks that receptor rather than activating it. The aprepitant family prevents chemotherapy-induced nausea and vomiting by blocking NK1. In October 2025 the FDA approved elinzanetant for menopausal hot flashes, and its mechanism is stated by its maker as inhibition of substance P.
- 03What happens when it is given to people nowThe Danish Headache Center is currently recruiting for a trial titled Substance P-Induced Migraine Attacks Without Aura. Participants with migraine receive a continuous intravenous infusion of substance P at 4.0 picomoles per kilogram per minute over 20 minutes, and the primary outcome is the incidence of migraine attacks in the 12 hours after the infusion starts against placebo. The purpose is to trigger attacks. That is the current state of substance P administration in humans: a provocation agent.
- 04The anti-aging paper, read properlyA 2019 paper in the International Journal of Molecular Sciences is titled Anti-Aging Potential of Substance P-Based Hydrogel for Human Skin Longevity. Three things about it matter. All three authors are at one company's research institute. The work is entirely laboratory work: cultured human fibroblasts, isolated keratinocytes and melanocytes, and a reconstructed three-dimensional skin model. No human subject was tested. The authors state this themselves in the discussion: the anti-aging effects of SP gel have not yet been demonstrated on human skin, and they describe a human irritation test as future work. A title containing the words Human Skin Longevity, over a study that tested no human skin, is the sort of gap worth noticing.
- 05Holding the two sides togetherThere is no contradiction in the underlying biology. Substance P promotes inflammation, and inflammation drives both the pain the approved drugs treat and the collagen response the laboratory paper measured. The question is which effect dominates on a living person's face, and no study has answered it. Given that the approved uses of this system all involve blocking substance P, the burden of proof on applying it sits high.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Approved medicine blocks it
FDA-approved- RegulatoryElinzanetant was approved by the FDA on October 24, 2025 for moderate to severe vasomotor symptoms due to menopause. Its maker states the mechanism as inhibition of substance P and neurokinin B through NK1 and NK3 antagonism.
- RegulatoryThe aprepitant family of NK1 receptor antagonists is licensed to prevent chemotherapy-induced nausea and vomiting, again by blocking the receptor substance P acts on.
- No dataNo approved drug supplies substance P. Every licensed agent on this system is an antagonist.
What it is currently given to people for
Early research- human-earlyAn actively recruiting trial infuses substance P intravenously at 4.0 picomoles per kilogram per minute in people with migraine, with the incidence of migraine attacks as the primary outcome. The aim is to provoke attacks.
- No dataNo trial gives substance P as a treatment for anything.
The anti-aging claim and what supports it
Research only- Lab studyOne 2019 paper proposes a substance P hydrogel as an anti-aging skin ingredient. All three authors work at the same company's research institute.
- Lab studyThe study used cultured cells and a reconstructed skin model. No human subject was tested.
- No dataThe authors write in their own discussion that the anti-aging effects have not yet been demonstrated on human skin, and that a human irritation test remains future work.
- No dataWe searched for finished cosmetic products containing substance P and did not find one offered for sale.
The anti-aging framing is the error worth catching. It traces to a single 2019 laboratory paper whose authors all work for one company and who state in their own discussion that the effects have not been demonstrated on human skin. The paper's title contains the phrase Human Skin Longevity, and the study tested no human skin, so a citation of the title alone badly overstates what was done. The second error is directional. Readers encountering substance P as a wellness ingredient are usually unaware that the only approved drugs touching this system block it, including a menopause drug approved in October 2025 whose stated mechanism is inhibition of substance P. Third, substance P is sometimes conflated with tachykinins generally or with neurokinin A; those come from the same precursor gene but are different peptides with different sequences. Last, a 10-residue sequence beginning with proline circulates in some listings, and the reference range is 11 residues beginning with arginine.
The published record
Papers and trials about Substance P
Searched: substance P migraine, substance P provocation, substance P hydrogel, substance P skin aging, elinzanetant.
Left out: substance P (the bare name returns on the order of tens of thousands of records across pain, inflammation, gastroenterology and neuroscience, swamping the two narrow questions this card addresses); tachykinin (the family term, covering neurokinin A and neuropeptide K from the same gene); neurokinin A (a different peptide from the same precursor, at residues 98 to 107); aprepitant (a marketed antiemetic with its own substantial literature); NK1 receptor (a receptor term dominated by antiemetic drug development); SP (an abbreviation matching an enormous amount of unrelated text).
64 papers tagged human · 35 not reviews or lab · 12 clinical trial publications
4 registered trials · none with posted results
Furthest stage reached: Published trials only, 12 clinical trial publications, no phased trial registered
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Substance P
Evidence
Category
Brain, mood and sleep
Common vial
Varies
Half-life
Minutes, not precisely established
How much, and do you cycle it?
The range, and whether you take breaks.No established dose, not applicable. Not applicable No range
There is no approved product and no established route of use, so no cycling scheme exists.
Minutes, not precisely establishedNo figure
No reliable human half-life figure was found in the sources read for this page. Native substance P is degraded very rapidly, and that is the practical reason research suppliers stock modified analogs more often than the natural sequence. No number is quoted here rather than giving one we could not source.
You can compare this against the whole library to see where it sits.
What does it cost?
Typical dose and cost, in plain numbers.Substance P is not injected in the forms covered here
It is not taken as a treatment.
How do you store it?
Before mixing, and after.Nothing to store: it is not taken as a treatment.
Substance P is not used as a medicine or a supplement, so no home storage question arises. Laboratory suppliers ship research material frozen and state their own handling conditions on the certificate that comes with it.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 36% charged residues, 55% hydrophobic. Water usually sufficient.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Any skin or anti-aging use: the one supporting paper is laboratory work by a single company and states in its own discussion that the effects have not been demonstrated on human skin
- Any use at all, since the direction of every approved drug acting on this receptor is to block substance P rather than supply it
Stop and get help
- Not applicable. There is no approved product and no established route of use.
Common effects
- Headache and migraine attacks, the effect the current human studies are designed to produce
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Substance P approved?
And where the numbers on this page come from.No. Substance P is not approved for any use, anywhere. It is sold labeled for laboratory research only, and there is no legal route to buy it for human use.
- Approval statusResearch only
- RouteNot taken as a treatment
- Checked26 October 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesUniProt P20366, human protachykinin-1Trial registry record NCT06959004, substance P migraine provocation trialKim, Chang and Lee, International Journal of Molecular Sciences, the anti-aging hydrogel paperBayer press release, FDA approval of Lynkuet (elinzanetant)Firazyr (icatibant) prescribing information, cited for the contrast
What has happened recently
Not approved anywhere as a therapy, and the regulatory activity around it runs in the opposite direction. The drugs licensed against this system are all NK1 receptor antagonists: the aprepitant family used to prevent chemotherapy-induced nausea and vomiting, and now elinzanetant, approved by the FDA on October 24, 2025 for moderate to severe vasomotor symptoms due to menopause. Bayer describes elinzanetant as the first dual neurokinin targeted therapy and states its mechanism as inhibition of substance P and neurokinin B through antagonism of NK1 and NK3 receptor signaling. That is the clearest possible statement of where the therapeutic value lies. Substance P itself is sold as a research reagent. We searched for finished cosmetic products containing substance P and did not find one, so the anti-aging proposal below appears to be a published idea rather than something currently on sale.
You can compare this against the whole library, or read how to check a seller.
What else is like Substance P?
Others in Brain, mood and sleep, side by side.If you're weighing Substance P, it's worth reading Trofinetide (Daybue), Ziconotide, and Selank in the same class.
Approved medicine blocks it. One paper suggests putting it on your face.
- Dose
- No established dose
- How often
- Not applicable
An approved oral treatment for Rett syndrome, built from the first three amino acids of IGF-1 with one methyl group added.
- Dose
- 5,000 to 12,000 mg twice daily by weight (label)
- How often
- Twice daily
The FDA-approved cone-snail peptide for severe chronic pain, delivered only into the spinal fluid.
- Dose
- 2.4 up to 19.2 mcg per day by continuous pump (label)
- How often
- Continuous infusion
A peptide that eases anxiety while keeping you clear-headed.
- Dose
- 0.25 up to 0.5 mg per day
- How often
- 1-2x daily
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- UniProt P20366, human protachykinin-1(2026)The reference sequence record, read positionally. The precursor is 129 amino acids. Substance P is annotated as residues 58 to 68, and counting the sequence from position 58 gives RPKPQQFFGLM, 11 residues, with a modification at position 68 recording the methionine amide. Neurokinin A is residues 98 to 107, giving HKTDSFVGLM with its own amide at 107. Neuropeptide K is 72 to 107 and neuropeptide gamma is annotated in two non-contiguous parts. Worth noting for anyone checking a vendor datasheet: a 10-residue version of substance P beginning at proline is a transcription error, since the annotated range begins one residue earlier at arginine.
- Trial registry record NCT06959004, substance P migraine provocation trial(2026)Titled Substance P-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial, sponsored by the Danish Headache Center with the principal investigator at Rigshospitalet. Recruiting, started May 13, 2025, estimated enrollment 21. The intervention is a continuous intravenous infusion of 20 mL of substance P at 4.0 picomoles per kilogram per minute over 20 minutes, against isotonic saline on the same schedule. Primary outcome is the difference in incidence of migraine attacks without aura between substance P and placebo during the 12 hours after the infusion begins, with headache intensity as a secondary outcome. The stated purpose is to examine whether substance P can trigger migraine attacks.
- Kim, Chang and Lee, International Journal of Molecular Sciences, the anti-aging hydrogel paper(2019)Anti-Aging Potential of Substance P-Based Hydrogel for Human Skin Longevity, volume 20, issue 18, article 4453, published September 10, 2019. All three authors are listed under a single affiliation, the Research and Development Institute at Biosolution in Seoul. The work is in vitro: human dermal fibroblasts, keratinocytes and melanocytes isolated from tissue, and a reconstructed three-dimensional skin model. No in vivo human testing is reported. The discussion states verbatim that the anti-aging effects of SP gel have not yet been demonstrated on human skin, that additional studies would be required to clarify the anti-aging effects, and that the authors will perform a primary irritation test using SP gel on human skin in the future. Reported findings are more collagen than substance P alone, an anti-inflammatory effect, improved absorption, and no induction of melanin synthesis in co-culture. DOI resolved at Crossref.
- Bayer press release, FDA approval of Lynkuet (elinzanetant)(2025)Dated October 24, 2025, announcing FDA approval that day for the treatment of moderate to severe vasomotor symptoms due to menopause, taken orally once daily. Describes the drug as the first dual neurokinin targeted therapy, an NK1 and NK3 receptor antagonist, and states the mechanism as inhibition of substance P and neurokinin B through antagonism of NK1 and NK3 receptor signaling on KNDy neurons. Cited here because it is the clearest regulatory statement that the therapeutic direction on this system is to block substance P.
- Firazyr (icatibant) prescribing information, cited for the contrast(2026)Included to make the same point from a second angle. Icatibant is described in its own label as a selective, competitive inhibitor of the bradykinin B2 receptor, used for acute attacks of hereditary angioedema at 30 mg subcutaneously. Bradykinin and substance P are different peptides on different receptors, and in both cases the approved medicine is an antagonist rather than the peptide itself.
Beyond these, 102 records are indexed. Browse the records